nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C9—cardial valve—dilated cardiomyopathy	0.0847	0.353	CbGeAlD
Sitaxentan—Dyspnoea paroxysmal nocturnal—Lisinopril—dilated cardiomyopathy	0.0525	0.0938	CcSEcCtD
Sitaxentan—Orthopnoea—Lisinopril—dilated cardiomyopathy	0.038	0.0678	CcSEcCtD
Sitaxentan—EDNRB—cardiac ventricle—dilated cardiomyopathy	0.0261	0.109	CbGeAlD
Sitaxentan—EDNRB—myocardium—dilated cardiomyopathy	0.0245	0.102	CbGeAlD
Sitaxentan—EDNRA—cardiac ventricle—dilated cardiomyopathy	0.0216	0.0899	CbGeAlD
Sitaxentan—EDNRA—myocardium—dilated cardiomyopathy	0.0203	0.0845	CbGeAlD
Sitaxentan—EDNRB—heart—dilated cardiomyopathy	0.0171	0.0714	CbGeAlD
Sitaxentan—EDNRB—cardiac atrium—dilated cardiomyopathy	0.0146	0.061	CbGeAlD
Sitaxentan—EDNRA—heart—dilated cardiomyopathy	0.0142	0.059	CbGeAlD
Sitaxentan—Polydipsia—Furosemide—dilated cardiomyopathy	0.0136	0.0243	CcSEcCtD
Sitaxentan—EDNRA—cardiac atrium—dilated cardiomyopathy	0.0121	0.0505	CbGeAlD
Sitaxentan—EDNRB—Endothelin Pathways—ADRB1—dilated cardiomyopathy	0.0101	0.0507	CbGpPWpGaD
Sitaxentan—Pancreatitis acute—Furosemide—dilated cardiomyopathy	0.00914	0.0163	CcSEcCtD
Sitaxentan—Breast pain—Spironolactone—dilated cardiomyopathy	0.00889	0.0159	CcSEcCtD
Sitaxentan—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00883	0.0157	CcSEcCtD
Sitaxentan—Atrial flutter—Lisinopril—dilated cardiomyopathy	0.00833	0.0149	CcSEcCtD
Sitaxentan—Flank pain—Lisinopril—dilated cardiomyopathy	0.00786	0.014	CcSEcCtD
Sitaxentan—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00762	0.0136	CcSEcCtD
Sitaxentan—Dysaesthesia—Lisinopril—dilated cardiomyopathy	0.00732	0.0131	CcSEcCtD
Sitaxentan—EDNRA—Endothelin Pathways—ADRB1—dilated cardiomyopathy	0.00725	0.0363	CbGpPWpGaD
Sitaxentan—Nephritis interstitial—Furosemide—dilated cardiomyopathy	0.00625	0.0112	CcSEcCtD
Sitaxentan—EDNRB—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.0059	0.0295	CbGpPWpGaD
Sitaxentan—EDNRA—EGFR-dependent Endothelin signaling events—EGFR—dilated cardiomyopathy	0.00586	0.0294	CbGpPWpGaD
Sitaxentan—Cholestasis—Furosemide—dilated cardiomyopathy	0.00556	0.00991	CcSEcCtD
Sitaxentan—Tubulointerstitial nephritis—Furosemide—dilated cardiomyopathy	0.00551	0.00983	CcSEcCtD
Sitaxentan—EDNRB—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.00548	0.0275	CbGpPWpGaD
Sitaxentan—Ataxia—Spironolactone—dilated cardiomyopathy	0.00529	0.00945	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00517	0.0259	CbGpPWpGaD
Sitaxentan—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00507	0.00905	CcSEcCtD
Sitaxentan—Psoriasis—Lisinopril—dilated cardiomyopathy	0.00504	0.00899	CcSEcCtD
Sitaxentan—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.00487	0.00869	CcSEcCtD
Sitaxentan—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00482	0.0086	CcSEcCtD
Sitaxentan—CYP2C9—heart—dilated cardiomyopathy	0.00468	0.0195	CbGeAlD
Sitaxentan—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00461	0.00822	CcSEcCtD
Sitaxentan—EDNRB—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.00453	0.0227	CbGpPWpGaD
Sitaxentan—Gout—Furosemide—dilated cardiomyopathy	0.00452	0.00806	CcSEcCtD
Sitaxentan—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.0043	0.00767	CcSEcCtD
Sitaxentan—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.00428	0.00763	CcSEcCtD
Sitaxentan—Renal failure—Spironolactone—dilated cardiomyopathy	0.00426	0.00761	CcSEcCtD
Sitaxentan—EDNRB—Endothelin Pathways—RAF1—dilated cardiomyopathy	0.00422	0.0212	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.00422	0.0211	CbGpPWpGaD
Sitaxentan—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.0042	0.0075	CcSEcCtD
Sitaxentan—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.00413	0.00738	CcSEcCtD
Sitaxentan—Otitis media—Lisinopril—dilated cardiomyopathy	0.00407	0.00726	CcSEcCtD
Sitaxentan—Memory impairment—Lisinopril—dilated cardiomyopathy	0.00403	0.0072	CcSEcCtD
Sitaxentan—EDNRA—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.00392	0.0196	CbGpPWpGaD
Sitaxentan—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.00382	0.00681	CcSEcCtD
Sitaxentan—EDNRB—Endothelins—RAC1—dilated cardiomyopathy	0.0038	0.019	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.0037	0.0185	CbGpPWpGaD
Sitaxentan—Mental disability—Furosemide—dilated cardiomyopathy	0.00366	0.00653	CcSEcCtD
Sitaxentan—Breast pain—Lisinopril—dilated cardiomyopathy	0.00363	0.00647	CcSEcCtD
Sitaxentan—Proteinuria—Lisinopril—dilated cardiomyopathy	0.0036	0.00643	CcSEcCtD
Sitaxentan—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.00358	0.00638	CcSEcCtD
Sitaxentan—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00355	0.00634	CcSEcCtD
Sitaxentan—Ventricular extrasystoles—Lisinopril—dilated cardiomyopathy	0.0035	0.00625	CcSEcCtD
Sitaxentan—Viral infection—Lisinopril—dilated cardiomyopathy	0.0035	0.00625	CcSEcCtD
Sitaxentan—Alopecia—Spironolactone—dilated cardiomyopathy	0.00344	0.00614	CcSEcCtD
Sitaxentan—Deafness—Furosemide—dilated cardiomyopathy	0.00342	0.00611	CcSEcCtD
Sitaxentan—Gout—Lisinopril—dilated cardiomyopathy	0.00339	0.00605	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.00332	0.0167	CbGpPWpGaD
Sitaxentan—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00326	0.00582	CcSEcCtD
Sitaxentan—EDNRA—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.00325	0.0163	CbGpPWpGaD
Sitaxentan—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.0032	0.00572	CcSEcCtD
Sitaxentan—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00317	0.00565	CcSEcCtD
Sitaxentan—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00317	0.00565	CcSEcCtD
Sitaxentan—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00315	0.00561	CcSEcCtD
Sitaxentan—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00311	0.00555	CcSEcCtD
Sitaxentan—Wheezing—Lisinopril—dilated cardiomyopathy	0.00307	0.00549	CcSEcCtD
Sitaxentan—Malaise—Spironolactone—dilated cardiomyopathy	0.00306	0.00546	CcSEcCtD
Sitaxentan—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00303	0.00541	CcSEcCtD
Sitaxentan—EDNRA—Endothelin Pathways—RAF1—dilated cardiomyopathy	0.00302	0.0151	CbGpPWpGaD
Sitaxentan—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00301	0.00536	CcSEcCtD
Sitaxentan—Photophobia—Lisinopril—dilated cardiomyopathy	0.00297	0.0053	CcSEcCtD
Sitaxentan—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00287	0.00512	CcSEcCtD
Sitaxentan—Discomfort—Spironolactone—dilated cardiomyopathy	0.00285	0.00509	CcSEcCtD
Sitaxentan—Dehydration—Furosemide—dilated cardiomyopathy	0.00285	0.00508	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.0028	0.00499	CcSEcCtD
Sitaxentan—Confusional state—Spironolactone—dilated cardiomyopathy	0.00279	0.00498	CcSEcCtD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00277	0.0139	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00277	0.0139	CbGpPWpGaD
Sitaxentan—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00276	0.00492	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—RAC1—dilated cardiomyopathy	0.00272	0.0136	CbGpPWpGaD
Sitaxentan—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00271	0.00483	CcSEcCtD
Sitaxentan—Muscular weakness—Furosemide—dilated cardiomyopathy	0.0027	0.00482	CcSEcCtD
Sitaxentan—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00265	0.00474	CcSEcCtD
Sitaxentan—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00262	0.00468	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.00261	0.0131	CbGpPWpGaD
Sitaxentan—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00259	0.00463	CcSEcCtD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00258	0.0129	CbGpPWpGaD
Sitaxentan—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00256	0.00456	CcSEcCtD
Sitaxentan—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00252	0.0045	CcSEcCtD
Sitaxentan—EDNRB—Endothelins—RAF1—dilated cardiomyopathy	0.00252	0.0126	CbGpPWpGaD
Sitaxentan—Somnolence—Spironolactone—dilated cardiomyopathy	0.00246	0.00439	CcSEcCtD
Sitaxentan—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00245	0.00436	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00242	0.00431	CcSEcCtD
Sitaxentan—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00241	0.00431	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00239	0.00426	CcSEcCtD
Sitaxentan—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00239	0.00426	CcSEcCtD
Sitaxentan—Arthritis—Lisinopril—dilated cardiomyopathy	0.00236	0.00422	CcSEcCtD
Sitaxentan—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00235	0.0042	CcSEcCtD
Sitaxentan—Renal failure—Furosemide—dilated cardiomyopathy	0.00232	0.00414	CcSEcCtD
Sitaxentan—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.0023	0.0041	CcSEcCtD
Sitaxentan—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00228	0.00407	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00223	0.00398	CcSEcCtD
Sitaxentan—Urticaria—Spironolactone—dilated cardiomyopathy	0.0022	0.00392	CcSEcCtD
Sitaxentan—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00219	0.0039	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00217	0.0109	CbGpPWpGaD
Sitaxentan—Ataxia—Lisinopril—dilated cardiomyopathy	0.00216	0.00386	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00216	0.0108	CbGpPWpGaD
Sitaxentan—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00215	0.00384	CcSEcCtD
Sitaxentan—Dehydration—Lisinopril—dilated cardiomyopathy	0.00214	0.00381	CcSEcCtD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.00213	0.0107	CbGpPWpGaD
Sitaxentan—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.0021	0.00374	CcSEcCtD
Sitaxentan—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00209	0.00373	CcSEcCtD
Sitaxentan—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00208	0.00371	CcSEcCtD
Sitaxentan—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00208	0.00371	CcSEcCtD
Sitaxentan—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00207	0.00369	CcSEcCtD
Sitaxentan—Visual impairment—Furosemide—dilated cardiomyopathy	0.00204	0.00364	CcSEcCtD
Sitaxentan—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00204	0.00364	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00202	0.0101	CbGpPWpGaD
Sitaxentan—Asthma—Lisinopril—dilated cardiomyopathy	0.00199	0.00354	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00198	0.00994	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00198	0.00994	CbGpPWpGaD
Sitaxentan—Eye disorder—Furosemide—dilated cardiomyopathy	0.00198	0.00353	CcSEcCtD
Sitaxentan—Tinnitus—Furosemide—dilated cardiomyopathy	0.00198	0.00352	CcSEcCtD
Sitaxentan—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00197	0.00351	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00195	0.00979	CbGpPWpGaD
Sitaxentan—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00193	0.00345	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00193	0.00967	CbGpPWpGaD
Sitaxentan—Angiopathy—Furosemide—dilated cardiomyopathy	0.00192	0.00343	CcSEcCtD
Sitaxentan—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00191	0.00341	CcSEcCtD
Sitaxentan—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00191	0.00341	CcSEcCtD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.0019	0.0095	CbGpPWpGaD
Sitaxentan—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00189	0.00338	CcSEcCtD
Sitaxentan—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00189	0.00337	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00186	0.00932	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00186	0.00932	CbGpPWpGaD
Sitaxentan—Dysuria—Lisinopril—dilated cardiomyopathy	0.00186	0.00331	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00185	0.00924	CbGpPWpGaD
Sitaxentan—Malnutrition—Furosemide—dilated cardiomyopathy	0.00184	0.00329	CcSEcCtD
Sitaxentan—Dizziness—Spironolactone—dilated cardiomyopathy	0.00183	0.00326	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00181	0.00323	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—RAF1—dilated cardiomyopathy	0.0018	0.00903	CbGpPWpGaD
Sitaxentan—Weight decreased—Lisinopril—dilated cardiomyopathy	0.0018	0.00321	CcSEcCtD
Sitaxentan—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00179	0.0032	CcSEcCtD
Sitaxentan—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00177	0.00316	CcSEcCtD
Sitaxentan—Vomiting—Spironolactone—dilated cardiomyopathy	0.00176	0.00314	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00175	0.00311	CcSEcCtD
Sitaxentan—Rash—Spironolactone—dilated cardiomyopathy	0.00174	0.00311	CcSEcCtD
Sitaxentan—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00174	0.00311	CcSEcCtD
Sitaxentan—Renal failure—Lisinopril—dilated cardiomyopathy	0.00174	0.00311	CcSEcCtD
Sitaxentan—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00174	0.0031	CcSEcCtD
Sitaxentan—Headache—Spironolactone—dilated cardiomyopathy	0.00173	0.00309	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00173	0.00866	CbGpPWpGaD
Sitaxentan—Jaundice—Lisinopril—dilated cardiomyopathy	0.00173	0.00308	CcSEcCtD
Sitaxentan—Anaemia—Furosemide—dilated cardiomyopathy	0.0017	0.00304	CcSEcCtD
Sitaxentan—Agitation—Furosemide—dilated cardiomyopathy	0.00169	0.00302	CcSEcCtD
Sitaxentan—Haematuria—Lisinopril—dilated cardiomyopathy	0.00169	0.00301	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00167	0.00299	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00167	0.00839	CbGpPWpGaD
Sitaxentan—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00167	0.00298	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00167	0.00836	CbGpPWpGaD
Sitaxentan—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00166	0.00296	CcSEcCtD
Sitaxentan—Vertigo—Furosemide—dilated cardiomyopathy	0.00166	0.00296	CcSEcCtD
Sitaxentan—Leukopenia—Furosemide—dilated cardiomyopathy	0.00165	0.00295	CcSEcCtD
Sitaxentan—Nausea—Spironolactone—dilated cardiomyopathy	0.00164	0.00293	CcSEcCtD
Sitaxentan—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00162	0.00289	CcSEcCtD
Sitaxentan—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00159	0.00284	CcSEcCtD
Sitaxentan—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00159	0.00284	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00158	0.00793	CbGpPWpGaD
Sitaxentan—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00157	0.0028	CcSEcCtD
Sitaxentan—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00157	0.00279	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00156	0.00278	CcSEcCtD
Sitaxentan—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00156	0.00278	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00155	0.00778	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00155	0.00774	CbGpPWpGaD
Sitaxentan—Dry mouth—Furosemide—dilated cardiomyopathy	0.00154	0.00274	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.00153	0.00764	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00152	0.00761	CbGpPWpGaD
Sitaxentan—Confusional state—Furosemide—dilated cardiomyopathy	0.00152	0.00271	CcSEcCtD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.0015	0.00751	CbGpPWpGaD
Sitaxentan—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00148	0.00264	CcSEcCtD
Sitaxentan—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00148	0.00263	CcSEcCtD
Sitaxentan—Flushing—Lisinopril—dilated cardiomyopathy	0.00148	0.00263	CcSEcCtD
Sitaxentan—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00147	0.00263	CcSEcCtD
Sitaxentan—Skin disorder—Furosemide—dilated cardiomyopathy	0.00146	0.00261	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00144	0.00723	CbGpPWpGaD
Sitaxentan—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00144	0.00257	CcSEcCtD
Sitaxentan—Anorexia—Furosemide—dilated cardiomyopathy	0.00143	0.00256	CcSEcCtD
Sitaxentan—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00143	0.00256	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00143	0.00716	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00142	0.00709	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00142	0.00709	CbGpPWpGaD
Sitaxentan—Hypotension—Furosemide—dilated cardiomyopathy	0.00141	0.00251	CcSEcCtD
Sitaxentan—Alopecia—Lisinopril—dilated cardiomyopathy	0.0014	0.00251	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.0014	0.00701	CbGpPWpGaD
Sitaxentan—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00139	0.00249	CcSEcCtD
Sitaxentan—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00138	0.00247	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00138	0.00692	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00136	0.00681	CbGpPWpGaD
Sitaxentan—Tension—Lisinopril—dilated cardiomyopathy	0.00136	0.00242	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00136	0.0068	CbGpPWpGaD
Sitaxentan—Nervousness—Lisinopril—dilated cardiomyopathy	0.00134	0.0024	CcSEcCtD
Sitaxentan—Somnolence—Furosemide—dilated cardiomyopathy	0.00134	0.00239	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00133	0.00667	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00133	0.00667	CbGpPWpGaD
Sitaxentan—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00133	0.00237	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00132	0.00659	CbGpPWpGaD
Sitaxentan—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00131	0.00233	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.0013	0.00232	CcSEcCtD
Sitaxentan—Fatigue—Furosemide—dilated cardiomyopathy	0.0013	0.00232	CcSEcCtD
Sitaxentan—Tremor—Lisinopril—dilated cardiomyopathy	0.0013	0.00231	CcSEcCtD
Sitaxentan—Constipation—Furosemide—dilated cardiomyopathy	0.00129	0.0023	CcSEcCtD
Sitaxentan—Pain—Furosemide—dilated cardiomyopathy	0.00129	0.0023	CcSEcCtD
Sitaxentan—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00128	0.00229	CcSEcCtD
Sitaxentan—Anaemia—Lisinopril—dilated cardiomyopathy	0.00128	0.00228	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00128	0.00639	CbGpPWpGaD
Sitaxentan—Malaise—Lisinopril—dilated cardiomyopathy	0.00125	0.00223	CcSEcCtD
Sitaxentan—Vertigo—Lisinopril—dilated cardiomyopathy	0.00124	0.00222	CcSEcCtD
Sitaxentan—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00124	0.00221	CcSEcCtD
Sitaxentan—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00124	0.00221	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00124	0.0062	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.0012	0.006	CbGpPWpGaD
Sitaxentan—Urticaria—Furosemide—dilated cardiomyopathy	0.0012	0.00213	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00119	0.00598	CbGpPWpGaD
Sitaxentan—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00119	0.00212	CcSEcCtD
Sitaxentan—Chest pain—Lisinopril—dilated cardiomyopathy	0.00118	0.0021	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00117	0.00209	CcSEcCtD
Sitaxentan—Discomfort—Lisinopril—dilated cardiomyopathy	0.00116	0.00208	CcSEcCtD
Sitaxentan—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00115	0.00206	CcSEcCtD
Sitaxentan—Confusional state—Lisinopril—dilated cardiomyopathy	0.00114	0.00203	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00113	0.00568	CbGpPWpGaD
Sitaxentan—Oedema—Lisinopril—dilated cardiomyopathy	0.00113	0.00202	CcSEcCtD
Sitaxentan—Infection—Lisinopril—dilated cardiomyopathy	0.00112	0.002	CcSEcCtD
Sitaxentan—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00111	0.00198	CcSEcCtD
Sitaxentan—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00111	0.00197	CcSEcCtD
Sitaxentan—Tachycardia—Lisinopril—dilated cardiomyopathy	0.0011	0.00197	CcSEcCtD
Sitaxentan—Skin disorder—Lisinopril—dilated cardiomyopathy	0.0011	0.00196	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00109	0.00545	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00109	0.00545	CbGpPWpGaD
Sitaxentan—Asthenia—Furosemide—dilated cardiomyopathy	0.00108	0.00193	CcSEcCtD
Sitaxentan—Anorexia—Lisinopril—dilated cardiomyopathy	0.00108	0.00192	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.00107	0.00538	CbGpPWpGaD
Sitaxentan—Hypotension—Lisinopril—dilated cardiomyopathy	0.00106	0.00188	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00103	0.00517	CbGpPWpGaD
Sitaxentan—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00103	0.00184	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00102	0.00513	CbGpPWpGaD
Sitaxentan—Insomnia—Lisinopril—dilated cardiomyopathy	0.00102	0.00182	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00101	0.00508	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00101	0.00508	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00101	0.00504	CbGpPWpGaD
Sitaxentan—Somnolence—Lisinopril—dilated cardiomyopathy	0.001	0.00179	CcSEcCtD
Sitaxentan—Dizziness—Furosemide—dilated cardiomyopathy	0.000995	0.00178	CcSEcCtD
Sitaxentan—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000994	0.00177	CcSEcCtD
Sitaxentan—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000982	0.00175	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000975	0.00174	CcSEcCtD
Sitaxentan—Fatigue—Lisinopril—dilated cardiomyopathy	0.000974	0.00174	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000973	0.00487	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000971	0.00486	CbGpPWpGaD
Sitaxentan—Constipation—Lisinopril—dilated cardiomyopathy	0.000966	0.00172	CcSEcCtD
Sitaxentan—Pain—Lisinopril—dilated cardiomyopathy	0.000966	0.00172	CcSEcCtD
Sitaxentan—Vomiting—Furosemide—dilated cardiomyopathy	0.000957	0.00171	CcSEcCtD
Sitaxentan—Rash—Furosemide—dilated cardiomyopathy	0.000949	0.00169	CcSEcCtD
Sitaxentan—Dermatitis—Furosemide—dilated cardiomyopathy	0.000948	0.00169	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000943	0.00472	CbGpPWpGaD
Sitaxentan—Headache—Furosemide—dilated cardiomyopathy	0.000943	0.00168	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000942	0.00472	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000931	0.00166	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000913	0.00457	CbGpPWpGaD
Sitaxentan—Urticaria—Lisinopril—dilated cardiomyopathy	0.000897	0.0016	CcSEcCtD
Sitaxentan—Nausea—Furosemide—dilated cardiomyopathy	0.000894	0.0016	CcSEcCtD
Sitaxentan—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000893	0.00159	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000841	0.00421	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000832	0.00148	CcSEcCtD
Sitaxentan—Asthenia—Lisinopril—dilated cardiomyopathy	0.00081	0.00145	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.0008	0.00401	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.0008	0.00401	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00078	0.0039	CbGpPWpGaD
Sitaxentan—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000773	0.00138	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000767	0.00384	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000766	0.00384	CbGpPWpGaD
Sitaxentan—Dizziness—Lisinopril—dilated cardiomyopathy	0.000747	0.00133	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000744	0.00373	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00074	0.0037	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000727	0.00364	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000727	0.00364	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000721	0.00361	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00072	0.00361	CbGpPWpGaD
Sitaxentan—Vomiting—Lisinopril—dilated cardiomyopathy	0.000718	0.00128	CcSEcCtD
Sitaxentan—Rash—Lisinopril—dilated cardiomyopathy	0.000712	0.00127	CcSEcCtD
Sitaxentan—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000711	0.00127	CcSEcCtD
Sitaxentan—Headache—Lisinopril—dilated cardiomyopathy	0.000708	0.00126	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000676	0.00338	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000675	0.00338	CbGpPWpGaD
Sitaxentan—Nausea—Lisinopril—dilated cardiomyopathy	0.000671	0.0012	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000654	0.00328	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000647	0.00324	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000616	0.00308	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000584	0.00292	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000573	0.00287	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000573	0.00287	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000559	0.0028	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000549	0.00275	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000533	0.00267	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00053	0.00266	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00052	0.00261	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00052	0.00261	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00052	0.00261	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000516	0.00258	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000489	0.00245	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000484	0.00242	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000484	0.00242	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000474	0.00238	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000468	0.00235	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000463	0.00232	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000453	0.00227	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000446	0.00223	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000441	0.00221	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000433	0.00217	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000429	0.00215	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000429	0.00215	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000418	0.00209	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000412	0.00206	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.0004	0.002	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000399	0.002	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000393	0.00197	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000387	0.00194	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00038	0.0019	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000346	0.00173	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.00033	0.00165	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000324	0.00162	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000313	0.00157	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00031	0.00155	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000307	0.00154	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000307	0.00154	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000295	0.00148	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000286	0.00143	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000282	0.00141	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000277	0.00139	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000273	0.00137	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000269	0.00135	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000243	0.00122	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000236	0.00118	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AGT—dilated cardiomyopathy	0.000232	0.00116	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	0.000232	0.00116	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000224	0.00112	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	0.000218	0.00109	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000211	0.00106	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	0.000199	0.000995	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	0.000197	0.000987	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000195	0.000978	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000193	0.000965	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000187	0.000937	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	0.00018	0.0009	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000174	0.000872	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AGT—dilated cardiomyopathy	0.000166	0.000833	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000161	0.000808	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000139	0.000698	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000134	0.000671	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000131	0.000656	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.00012	0.000602	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000118	0.000593	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000117	0.000586	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000115	0.000578	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000111	0.000554	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.00011	0.000549	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000107	0.000534	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000105	0.000528	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	9.61e-05	0.000481	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—dilated cardiomyopathy	7.91e-05	0.000396	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	5.35e-05	0.000268	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	5.21e-05	0.000261	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	4.88e-05	0.000244	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	4.75e-05	0.000238	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	4.69e-05	0.000235	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	4.28e-05	0.000214	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	3.22e-05	0.000161	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	3.13e-05	0.000157	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.82e-05	0.000141	CbGpPWpGaD
